No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers

Clinical Pharmacokinetics

Volumn 42, Issue 5, 2003, Pages 475-484

  Johansson, Linda C ^a   Andersson, Magnus ^a   Fager, Gunnar ^a   Gustafsson, David ^a   Eriksson, Ulf G ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MELAGATRAN; THROMBIN INHIBITOR; XIMELAGATRAN;

ADULT; AFRICAN; AREA UNDER THE CURVE; ARTICLE; ASIAN; BODY WEIGHT; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; ETHNIC GROUP; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; AZETIDINES; BENZYLAMINES; CONTINENTAL POPULATION GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GLYCINE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; PRODRUGS; THROMBIN;

EID: 0038526281     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342050-00005     Document Type: Article

References (21)

1. Eriksson UG, Bredberg U, Hoffmann K-J, et al. Absorption, distribution, metabolism, and excretion of the oral direct thrombin inhibitor, ximelagatran, in rats, dogs, and humans. Drug Metab Dispos 2003; 31: 294-305
2. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 1286-92
3. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 187-97
4. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110-8
5. Mehta JL, Chen L, Nichols WW, et al. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 1998; 31: 345-51
6. Eriksson BI, Carlsson S, Halvarsson M, et al. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 1997; 78: 1404-7
7. Mattsson C, Björkman J-A, Ulvinge J-C. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis Proteolysis 1997; 11: 121-8
8. Boström SL, Sarich TC, Wolzt M. H 376/95, an oral, direct thrombin inhibitor, and melagatran, its active form, delay and inhibit thrombin generation [abstract]. Haemostasis 2000; 36: 56
9. Sarich TC, Eriksson UG, Mattsson C, et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002; 87: 300-5
10. Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet 2002; 360: 1441-7
11. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-21
12. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002; 137: 648-55
13. Eriksson H, Wåhlander K, Gustafsson D, et al. A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41-7
14. Petersen P, SPORTIF II and IV investigators. A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation [abstract]. Blood 2001; 98: 706a
15. Eriksson UG, Bredberg U, Gislén K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young, healthy male subjects. Eur J Clin Pharmacol 2003. In press.
16. Eriksson UG, Mandema JW, Karlsson MO, et al. Pharmacokinetics of melagatran find the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clin Pharmacokinet. In press
17. Johansson L, Frison L, Logren U, et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct throrabin inhibitor. Clin Pharmacokinet 2003; 42: 381-92
18. Wood AJ. Ethnic differences in drug disposition and response. Ther Drug Monit 1998; 20: 525-6
19. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50
20. Larsson M, Logren U, Ahnoff M, et al. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 47-55
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41